Bruker Co. (NASDAQ: BRKR), Arcos Dorados Holdings Inc. (NASDAQ: ARCO), SPX Corp (NYSE: SPW), Atmel (NASDAQ: ATML), Entropic Communications (NASDAQ: ENTR), ON Semiconductor (NASDAQ: ONNN), Genpact Limited (NYSE: G), Lincoln Educational Services Corp (NASDAQ: LINC) and Owens Corning (NYSE: OC) price targets adjusted by analysts.
Arcos Dorados Holdings Inc. (ARCO) had its price target raised by Citigroup (NYSE:C) to $32.00. They have a “Buy” rating on the company.
Atmel (NASDAQ: ATML) had its price target lowered by analysts at UBS AG to $18.00. The analysts now have a “buy” rating on the company.
Bruker Co. (NASDAQ: BRKR) had its price target lowered by analysts at UBS AG from $23.00 to $21.00. The analysts now have a “buy” rating on the company.
Entropic Communications (NASDAQ: ENTR) had its price target lowered by analysts at The Benchmark Company from $12.00 to $9.00. The analysts now have a “buy” rating on the company.
Genpact Limited (NYSE: G) had its price target raised by analysts at Citigroup to $18.00. The analysts now have a “hold” rating on the company.
Lincoln Educational Services Corp (NASDAQ: LINC) had its price target lowered by analysts at Barrington Research from $23.00 to $19.00. The analysts now have an “outperform” rating on the company.
Owens Corning (NYSE: OC) had its price target lowered by analysts at Citigroup to $47.00. The analysts now have a “buy” rating on the company.
ON Semiconductor (NASDAQ: ONNN) had its price target lowered by analysts at UBS AG to $9.00. The analysts now have a “neutral” rating on the company.
SPX Corp (NYSE: SPW) had its price target lowered by analysts at Stifel Nicolaus from $100.00 to $90.00. The analysts now have a “buy” rating on the company.
Showing posts with label Bruker. Show all posts
Showing posts with label Bruker. Show all posts
Friday, August 5, 2011
Tuesday, January 11, 2011
Bruker (Nasdaq:BRKR) Has Room for Margin, Cash Flow Growth
Bruker Corp. (Nasdaq:BRKR) has room for margin and cash flow growth, said UBS (NYSE:UBS), citing new products from acquisitions and internal initiatives.
UBS said, "After a number of prior false starts, during 2010 BRKR proved that the company was capable of delivering real operating leverage. BRKR’s new products (both organic & acquired) diversify and expand the company’s reach, while there is ample room for further operational improvements to help drive more margin expansion and cash flow growth.
"Although tougher comparisons from sales related to 4Q09 stimulus funding will likely keep Q4 organic growth below the double-digit levels seen during Q1-Q3, consensus expectations look reasonable and BRKR’s preliminary FY11 appears conservative. We see Q4 sales of $385M & EPS of $0.27; we est. 2011-12 sales of $1,505M & $1,665M, respectively, with EPS of $0.90 & $1.05 (was $1.03)."
Bruker closed Monday at $17.01, gaining $1.01, or 6.31 percent. UBS raised their price target on them from $17 to $21, and boosted their rating from "Neutral" to "Buy."
UBS said, "After a number of prior false starts, during 2010 BRKR proved that the company was capable of delivering real operating leverage. BRKR’s new products (both organic & acquired) diversify and expand the company’s reach, while there is ample room for further operational improvements to help drive more margin expansion and cash flow growth.
"Although tougher comparisons from sales related to 4Q09 stimulus funding will likely keep Q4 organic growth below the double-digit levels seen during Q1-Q3, consensus expectations look reasonable and BRKR’s preliminary FY11 appears conservative. We see Q4 sales of $385M & EPS of $0.27; we est. 2011-12 sales of $1,505M & $1,665M, respectively, with EPS of $0.90 & $1.05 (was $1.03)."
Bruker closed Monday at $17.01, gaining $1.01, or 6.31 percent. UBS raised their price target on them from $17 to $21, and boosted their rating from "Neutral" to "Buy."
Subscribe to:
Posts (Atom)